Clinical trial · Expanded Access
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412
NCT02090127CI-TRIAL-00018707no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mullerian Mixed Tumor of Ovary | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ficlatuzumab | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Per original P05538 protocol Exclusion Criteria: * Per original P05538 protocol
References
Publications (0)
Data not yet available
No reference posted for this study.